Kimia Farma Tbk PT
IDX:KAEF

Watchlist Manager
Kimia Farma Tbk PT Logo
Kimia Farma Tbk PT
IDX:KAEF
Watchlist
Price: 600 IDR Market Closed
Market Cap: 3.3T IDR
Have any thoughts about
Kimia Farma Tbk PT?
Write Note

Kimia Farma Tbk PT
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kimia Farma Tbk PT
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Kimia Farma Tbk PT
IDX:KAEF
Revenue
Rp10.1T
CAGR 3-Years
-7%
CAGR 5-Years
2%
CAGR 10-Years
8%
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Revenue
Rp13.5T
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
6%
Kalbe Farma Tbk PT
IDX:KLBF
Revenue
Rp32.1T
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
6%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Revenue
Rp2.1T
CAGR 3-Years
0%
CAGR 5-Years
3%
CAGR 10-Years
7%
Soho Global Health Tbk PT
IDX:SOHO
Revenue
Rp8.2T
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
Revenue
Rp1.3T
CAGR 3-Years
40%
CAGR 5-Years
40%
CAGR 10-Years
20%
No Stocks Found

Kimia Farma Tbk PT
Glance View

Market Cap
3.3T IDR
Industry
Pharmaceuticals

PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.

KAEF Intrinsic Value
1 036.37 IDR
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Kimia Farma Tbk PT's Revenue?
Revenue
10.1T IDR

Based on the financial report for Sep 30, 2024, Kimia Farma Tbk PT's Revenue amounts to 10.1T IDR.

What is Kimia Farma Tbk PT's Revenue growth rate?
Revenue CAGR 10Y
8%

Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Kimia Farma Tbk PT have been -7% over the past three years , 2% over the past five years , and 8% over the past ten years .

Back to Top